Suboptimal dosages of TRAIL had mild to moderate effects on cellular viability in U87 (88.46%±0.2928), U373 (53.58%±0.7463) and LN229 GBM cells (81.33%±9.783) (Fig. 1A–C). This evidence concerns the gene TNFSF10 and glioblastoma.